Skip to main content
. 2023 Aug 18;16(5):434–441. doi: 10.1161/CIRCGEN.123.004059

Figure 3.

Figure 3.

Survival analyses comparing the RBM20LVSD and idiopathic left ventricular systolic dysfunction (iLVSD) cohorts. Kaplan-Meier curves comparing outcomes from baseline between RBM20LVSD and iLVSD cohorts for the primary composite end point (A), the secondary malignant ventricular arrhythmia end point (B), and the secondary end-stage heart failure end point (C). The RBM20LVSD cohort had significantly worse outcomes at 5 years for all end points in comparison with the iLVSD cohort.